| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 02/05/2004 | US20040024066 E.g., N-(2-(Benzo(b)thiophen-5-ylmethanesulfonyl)-1-(3,4-dichloro- phenyl)- ethyl)-N-hydroxyformamide; gene expression inhibitors of s-CD23; autoimmune disease; antiallergens; matrix metalloprotease enzyme inhibitors |
| 02/05/2004 | US20040024062 Inhibiting a condition mediated by the alpha v beta 3 or alpha v beta 5 integrin; antitumor, -metastasis, -arthritic agents; angiogenesis, inhibitors; osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration |
| 02/05/2004 | US20040024060 Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 02/05/2004 | US20040024059 Novel pleuromutilin derivatives |
| 02/05/2004 | US20040024052 Processes for preparing crystalline and amorphous mupirocin calcium |
| 02/05/2004 | US20040024049 Cytotoxic agents containing novel potent taxanes and their therapeutic use |
| 02/05/2004 | US20040024040 Inhibitors of GSK-3 and uses thereof |
| 02/05/2004 | US20040024030 Such as 4-chloro-5-(2-phenyl-thiazol-5-yl)-2H-pyrazole-3-carboxylic acid ethyl amide; for inhibiting topoisomerases; treating bacterial infections in mammals |
| 02/05/2004 | US20040024018 Sustained-release preparations of quinolone antibiotics and method for preparation thereof |
| 02/05/2004 | US20040024014 Such as 2-(nitrooxy)ethyl-2-(((3-methyl-4-(2,2,2-trifluoro-ethoxy)-2 -pyridyl)methyl)sulfinyl)benzimidazolecarboxylate; kits; for treating gastrointestinal disorders/ulcers |
| 02/05/2004 | US20040024000 Dihydropyrimidine derivatives as cysteine protease inhibitors |
| 02/05/2004 | US20040023992 Antiinflammatory agents |
| 02/05/2004 | US20040023991 Use of pyrazolo[4,3-d]pyrimidines |
| 02/05/2004 | US20040023974 Pharmacological agents which are inhibitors of PTPases, in particular, the compounds of formula I inhibit PTP-1B and TC PTP, and thus may be employed for the treatment of conditions associated with PTPase activity. The compounds of the present |
| 02/05/2004 | US20040023968 Phthalazinone derivatives |
| 02/05/2004 | US20040023963 Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| 02/05/2004 | US20040023961 Aryl ureas with raf kinase and angiogenisis inhibiting activity |
| 02/05/2004 | US20040023958 Compounds of formula I are hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) inhibitors, and are useful in therapeutic and prophylactic treatment of persons infected with hepatitis C virus. |
| 02/05/2004 | US20040023956 New intermediates and synthetic methods for the stereospecific synthesis of oxazinone compounds, which are useful, for example, as antibiotics. The invention also pertains to novel olefinic oxazinone compounds, methods for |
| 02/05/2004 | US20040023950 N-heterocyclic derivatives as NOS inhibitors |
| 02/05/2004 | US20040023947 Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| 02/05/2004 | US20040023945 Cyclic amp-specific phosphodiesterase inhibitors |
| 02/05/2004 | US20040023943 A cephem compound (particularly its crystal) represented by the formula (I), wherein X is CH3COOH, CH3CH2COOH or CH3CN, and n is 0 to 5, is useful as an antibacterial agent (particularly anti-MRSA agent) and shows superior quality such |
| 02/05/2004 | US20040023932 Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the |
| 02/05/2004 | US20040023901 Novel nucleoside bases and phosphate moiety mimics optionally having sugar-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a |
| 02/05/2004 | US20040023898 Single dose azithromycin |
| 02/05/2004 | US20040023897 Methods for preventing or treating disease mediated by toxin-secreting bacteria |
| 02/05/2004 | US20040023896 Compounds as antibacterial agents that may be used to treat various bacterial and protozoa infections. The invention also relates to drugs for bacterial protozoa infections by administering the compounds of formula 1. |
| 02/05/2004 | US20040023895 Macrolides possessing a 3-oxo moiety in place of the 3-cladinose sugar. or "ketolides" have displayed significant in vitro and in vivo activity against H.influenzae and multiresistant pneumococci |
| 02/05/2004 | US20040023893 Coumarin derivatives for treatment of vascular disorders, skin disorders or allergies |
| 02/05/2004 | US20040023883 IGF-I and insulin variants are provided that selectively bind to IGFBP-1 or IGFBP-3. These agonist variants are useful, for example, to improve the half-lives of IGF-I and insulin, respectively. |
| 02/05/2004 | US20040023869 Interleukin-1 inhibitors in the treatment of diseases |
| 02/05/2004 | US20040023859 New melanocortin receptor ligands are cyclic peptide analogs that preferably exhibit selectivity for the MC-4 and/or the MC-3 receptors relative to the other melanocortin receptors |
| 02/05/2004 | US20040023858 Antifungal combination therapy |
| 02/05/2004 | US20040023854 Adiponectin and uses thereof |
| 02/05/2004 | US20040023334 Comprises lactoferrin fusion protein for diagnosis, prevention treatment and prognosis of nervous system, respiratory, cardiovascular and/or reproductive system disorders |
| 02/05/2004 | US20040023332 Genes of il-12p40 subunit mutated for improving the activity of il-12 and thereof for dna vaccine adjuvant |
| 02/05/2004 | US20040023290 Novel therapeutic agents that modulate enzymatic processes |
| 02/05/2004 | US20040023257 Comprises nucleotide sequences coding proteolytic enzymes for increasing flavor in food, promoting microbiocidal activity, modifying and deprotecting chemical intermediates, synthesis and hydrolysis of cephalosporins |
| 02/05/2004 | US20040023240 Combinatorial production of nucleotide and nucleoside(xitp)analogues |
| 02/05/2004 | US20040022871 Halogenated composition, method for preparing same and uses thereof |
| 02/05/2004 | US20040022869 Containing microtubule stabilizing agents and one or more heat shock protein (HSP)-inducing agents; treating a proliferative disorder, an infectious disease, a cardiovascular disease, an autoimmune disorder, or an inflammatory disorder |
| 02/05/2004 | US20040022866 Use of sodium and potassium salts of citric, phosphoric, carbonic and tartaric acid and arginine and lysine as stabilizer of the antibiotic Fosfomycin Tromethamine |
| 02/05/2004 | US20040022846 Reduced side-effects |
| 02/05/2004 | US20040022831 For therapy of mycosis of the nail |
| 02/05/2004 | US20040022810 Immunomodulatory preparation |
| 02/05/2004 | US20040022809 Cold-adapted equine influenza viruses |
| 02/05/2004 | US20040022808 Use of a split enveloped virus preparation which is not a split influenza virus preparation in the manufacture of vaccine formulation for itranasal delivery |
| 02/05/2004 | US20040022801 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 02/05/2004 | US20040022800 Respiratory syncytial virus vaccine |
| 02/05/2004 | US20040022798 Can stored for several years, and which are ready to use after thawing |
| 02/05/2004 | US20040022783 Binding agents to CD23 |
| 02/05/2004 | US20040022781 Proteins and nucleic acids encoding same |
| 02/05/2004 | US20040022777 Fragments and antagonists of heat shock protein 60 |
| 02/05/2004 | US20040022774 Fibrocyte-based vaccine formulations |
| 02/05/2004 | US20040022772 Bcr-Abl directed compositions and uses for inhibiting Philadelphia chromosome stimulated cell growth |
| 02/05/2004 | US20040022763 Human recombinant beta-interferon with improved solubility |
| 02/05/2004 | US20040022762 Use of il-8 protein modulators in the treatment of viral infections |
| 02/05/2004 | US20040022760 Administering Flt3-ligand to a subject; optionally administering an auxiliary molecule; administering a vaccine to the subject, wherein the vaccine comprises an antigen and an adjuvant |
| 02/05/2004 | US20040022759 Ionic polymers as anti-infective agents |
| 02/05/2004 | DE10233064A1 gM-negative EHV-Mutanten ohne heterologe Elemente gM-negative EHV mutants without heterologous elements |
| 02/05/2004 | DE10231370A1 Neue Thiophenglycosidderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung Thiophenglycosidderivate new, processes for their preparation, pharmaceutical compositions containing them and their use |
| 02/05/2004 | CA2727782A1 Canine respiratory coronavirus (crcv) spike protein, polymerase and hemagglutinin/esterase |
| 02/05/2004 | CA2494485A1 Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies |
| 02/05/2004 | CA2494358A1 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 02/05/2004 | CA2494069A1 Pellicle-resistant gelatin capsule |
| 02/05/2004 | CA2493980A1 Gelatin capsule exhibiting reduced cross-linking |
| 02/05/2004 | CA2493949A1 Modified small interfering rna molecules and methods of use |
| 02/05/2004 | CA2493878A1 Parenteral formulations containing a rapamycin hydroxyester |
| 02/05/2004 | CA2493751A1 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 02/05/2004 | CA2493590A1 Auto-stimulating cells and method for making and using the same |
| 02/05/2004 | CA2493172A1 Method of treating tumors |
| 02/05/2004 | CA2493158A1 Preparation of 1h-imidazo [4,5-c] quinolin-4-amines via novel 1h-imidazo [4,5-c] quinolin-4-cyano and 1h-imidazo [4,5-c] quinolin-4-carboxamide intermediates |
| 02/05/2004 | CA2493156A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 02/05/2004 | CA2493078A1 Medicament dispenser |
| 02/05/2004 | CA2492607A1 Anti-viral 7-deaza d-nucleosides and uses thereof |
| 02/05/2004 | CA2492333A1 Canine respiratory coronavirus (crcv) spike protein, polymerase and hemagglutinin/esterase |
| 02/05/2004 | CA2491078A1 Percutaneous and perungual delivery system |
| 02/05/2004 | CA2488860A1 Method of preparing solid dosage forms coated in two layers comprising a water-insoluble polymer and a water-soluble pore former |
| 02/05/2004 | CA2484941A1 Antigens encoded by alternative reading frame from pathogenic viruses |
| 02/04/2004 | EP1386932A1 Improved humanized immunoglobulins |
| 02/04/2004 | EP1386928A1 A frog skin antibacterial peptide derivative |
| 02/04/2004 | EP1386923A1 Novel adenine derivatives |
| 02/04/2004 | EP1386616A1 Antibordetella vaccine |
| 02/04/2004 | EP1386614A1 Herbal pharmaceutical composition for treatment of hiv/aids patients |
| 02/04/2004 | EP1386166A2 Anti-epileptogenic agents |
| 02/04/2004 | EP1385988A2 Selective covalent-binding compounds having therapeutic diagnostic and analytical applications |
| 02/04/2004 | EP1385981A2 Antifungal compounds and methods of use |
| 02/04/2004 | EP1385977A2 Secreted proteins |
| 02/04/2004 | EP1385966A2 Recombinant fusion proteins and the trimers thereof |
| 02/04/2004 | EP1385952A2 Methods of inhibiting expression of a target gene in mammalian cells |
| 02/04/2004 | EP1385937A1 Delivery of polynucleotide agents to the central nervous sysstem |
| 02/04/2004 | EP1385934A2 Pufa polyketide synthase systems and uses thereof |
| 02/04/2004 | EP1385886A1 Method for preparing human immunoglobulin concentrates for therapeutic use |
| 02/04/2004 | EP1385883A2 Transmembrane proteins |
| 02/04/2004 | EP1385878A2 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds |
| 02/04/2004 | EP1385876A2 Gonococcal proteins and nucleic acids |
| 02/04/2004 | EP1385875A2 Epitopes of virus hepatitis c specifically cd4+ t-lymphocytes |
| 02/04/2004 | EP1385870A2 Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 02/04/2004 | EP1385864A1 Vascular endothelial growth factor 2 |